At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years at informed consent
- ✓Histologically or cytologically confirmed metastatic adenocarcinoma or poorly differentiated carcinoma of the prostate
- ✓Surgically or medically castrated with serum testosterone ≤50 ng/dL (1.73 nM)
- ✓Disease progression after one prior next-generation androgen receptor-targeted therapy
- ✕Active second malignancy (except curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer)
- ✕Prior treatment with any PARP inhibitor
- ✕Prior chemotherapy for metastatic castration-resistant prostate cancer
- ✕Symptomatic and/or untreated central nervous system metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency
In Brief
A Phase 3 clinical trial evaluating Rucaparib and Abiraterone acetate or Enzalutamide or Docetaxel for Metastatic Castration Resistant Prostate Cancer. Completed, enrolled 405 participants across 150 sites in 12 countries.
Detailed Summary
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
Study Details
Timeline
Interventions
Rucaparib will be administered daily.
Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.